Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

593.17 -1.15 (-0.19%)
Streaming Delayed Price Updated: 1:34 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
49 50 Next >
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Regeneron and Sarepta Therapeutics have been on fire so far this year. 
Via The Motley Fool
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Via Benzinga
2 Biotech Stocks That Could Help Set You Up for Life
The two companies have seen similar share growth over the past year. 
Via The Motley Fool
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
The French drug company got the nod for a hemophilia treatment. 
Via The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Via Benzinga
Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
Via Benzinga
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
3 More Mid-Cap Biotechs The Street Sees Doubling
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk. 
Via MarketBeat
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients. 
Via Investor's Business Daily
Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Top Healthcare Stocks Defying the Bear Market
These companies have impeccable long-term investment theses. 
Via The Motley Fool
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
New 52-Week Highs In 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023. 
Via Talk Markets
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
Via Benzinga
New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder
Via Benzinga
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential. 
Via InvestorPlace
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report. 
Via Investor's Business Daily
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.